Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

February 19, 2014Open Access

Ver artículo completo

Improved Survival with Bevacizumab in Advanced Cervical Cancer

KTKrishnansu S. TewariUniversity of California, Irvine Medical Center MSMichael W. SillRoswell Park Comprehensive Cancer Center HLHarry J. LongCreighton University

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Improved Survival with Bevacizumab in Advanced Cervical Cancer | Synapse

Cite This Study

Tewari et al. (Wed,) studied this question.

synapsesocial.com/papers/69d768fff44a16d01ef30d86 https://doi.org/https://doi.org/10.1056/nejmoa1309748

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.2010 · 23 citations
2PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel2011 · 10 citations
3Cancer statistics, 20132013 · 11,904 citations
4Discrete Sequential Boundaries for Clinical Trials1983 · 1,709 citations
5Multimodality Therapy for Locally Advanced Cervical Carcinoma: State of the Art and Future Directions2007 · 264 citations